Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUVOX vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Premenstrual dysphoric disorder (PMDD),Bulimia nervosa,Post-traumatic stress disorder (PTSD)
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
8 mg orally once daily, taken at bedtime.
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Primarily hepatic via CYP1A2; minor pathways via CYP2D6; active metabolites minimal.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
The apparent volume of distribution is about 4.7 L/kg, indicating extensive extravascular distribution and tissue binding, which contributes to its long half-life.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral bioavailability is approximately 53% after a single dose, with no significant food effect. Bioavailability may be higher under steady-state conditions due to saturation of first-pass metabolism.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥20 m L/min). Avoid use in severe renal impairment (Cr Cl <20 m L/min) due to lack of data.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
Child-Pugh Class A: no dose adjustment; Child-Pugh Class B: reduce dose by 50% (start 25 mg/day, titrate cautiously); Child-Pugh Class C: contraindicated.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Children (8-17 years): start 25 mg orally once daily at bedtime; increase by 25 mg increments every 4-7 days to target dose; for OCD: 25-200 mg/day; maximum 200 mg/day. Weight not routinely used; dosing based on age and response.
Not approved for use in pediatric patients; safety and efficacy not established.
Start 25 mg orally once daily at bedtime; titrate slowly (increases of 25 mg every 1-2 weeks); usual maximum 200 mg/day due to increased sensitivity and risk of hyponatremia.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in young patients,Serotonin syndrome,Activation of mania/hypomania,Seizure risk,Abnormal bleeding,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction,Discontinuation syndrome
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Concomitant use with MAOIs,Concomitant use with triptans,Hypersensitivity to fluvoxamine or any excipient,Pregnancy (relative)
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Avoid grapefruit juice as it inhibits CYP1A2 and can increase fluvoxamine serum concentrations, leading to toxicity. No other significant food interactions; however, taking with food may reduce GI upset.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hypertension of the newborn (PPHN) (OR 2.1). Second/third trimester: Late pregnancy exposure may increase risk of preterm birth, low birth weight, and neonatal adaptation syndrome (e.g., respiratory distress, feeding difficulties, irritability).
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Fluvoxamine is excreted into breast milk; M/P ratio ranges from 0.29 to 0.59. Relative infant dose is approximately 1.7% of maternal weight-adjusted dose. Low risk of adverse effects in breastfed infants; monitor for drowsiness, poor feeding, and weight gain. AAP classifies as compatible with breastfeeding.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Plasma levels of fluvoxamine may decrease during pregnancy due to increased volume of distribution and enhanced hepatic metabolism. Dose adjustment may be necessary; consider therapeutic drug monitoring to maintain efficacy. Usually, dose can be increased by 50-100% in third trimester, with gradual reduction postpartum to pre-pregnancy levels.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
Luvox (fluvoxamine) is a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder (OCD) and social anxiety disorder. It has a short half-life (15-22 hours) and no active metabolites, making it suitable for patients with hepatic impairment. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic agents. Luvox is a potent inhibitor of CYP1A2, affecting metabolism of drugs like clozapine, olanzapine, theophylline, and tizanidine. Titrate slowly; start at 50 mg nightly and increase by 50 mg every 4-7 days to a max of 300 mg daily (divided for doses >100 mg). Discontinuation syndrome is common; taper gradually.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take Luvox exactly as prescribed, usually once daily at bedtime to minimize daytime drowsiness.,It may take several weeks to feel the full effect; do not stop abruptly without consulting your doctor.,Avoid grapefruit juice, which can increase Luvox levels and side effects.,Report any signs of serotonin syndrome (hallucinations, agitation, rapid heart rate, fever, muscle stiffness) immediately.,Do not drive or operate heavy machinery until you know how Luvox affects you, as it can cause drowsiness or dizziness.,Limit alcohol consumption; alcohol can worsen sedation and increase risk of side effects.,Store at room temperature, away from moisture and heat.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
"Tetracycline may inhibit the metabolism of Fluvoxamine via cytochrome P450 enzyme interference, leading to increased Fluvoxamine plasma concentrations. This elevation potentiates serotonergic effects and may precipitate serotonin syndrome, characterized by hyperthermia, autonomic instability, and neuromuscular abnormalities. Concurrent use requires careful monitoring for signs of toxicity such as agitation, confusion, and tachycardia."
"Dexlansoprazole, a proton pump inhibitor (PPI), may inhibit CYP1A2, the primary enzyme responsible for metabolizing fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). This interaction can lead to increased plasma concentrations of fluvoxamine, potentiating its serotonergic effects and risk of dose-dependent adverse events such as nausea, somnolence, and serotonin syndrome. Clinicians should monitor for signs of fluvoxamine toxicity and consider dose adjustment when initiating or discontinuing dexlansoprazole."
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUVOX vs BRISDELLE, answered by our medical review team.
LUVOX is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUVOX and BRISDELLE depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUVOX is: Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUVOX and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUVOX is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hype. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.